CLIMB BIO INC (CLYM:NASDAQ)
$12.7 0.12 (0.9539%)
Analysed CLIMB BIO INC (CLYM:NASDAQ) News Sources
Climb Bio (CLYM) Enters Agreement for $110M Private Placement Financing
05-05-2026
yahoo.com
Climb Bio Spotlights Budoprutug CD19 Strategy, Sets Up 2026 Data Readouts in pMN, ITP and SLE
05-05-2026
marketbeat.com
Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
07-05-2026
yahoo.com
Climb Bio to Present at Upcoming Investor Conferences
12-05-2026
yahoo.com
Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress
14-05-2026
yahoo.com
Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect
21-05-2026
marketbeat.com
Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026
26-05-2026
yahoo.com
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development
05-06-2026
yahoo.com
Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026
11-06-2026
yahoo.com
Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year?
08-07-2026
yahoo.com
What is the current price of CLIMB BIO INC (CLYM:NASDAQ)?
The current price of CLIMB BIO INC (CLYM:NASDAQ) is $12.7.
CLIMB BIO INC (CLYM:NASDAQ) absolute price change since previous trading day?
The absolute price change of CLIMB BIO INC (CLYM:NASDAQ) since the previous trading day is $0.12.
CLIMB BIO INC (CLYM:NASDAQ) percentage price change since previous trading day?
The percentage price change of CLIMB BIO INC (CLYM:NASDAQ) since the previous trading day is 0.9539%.
What is the most recent average sentiment score for CLIMB BIO INC (CLYM:NASDAQ)?
The most recent average sentiment score for CLIMB BIO INC (CLYM:NASDAQ) is 82 out of 100.
What is the most recent average sentiment for CLIMB BIO INC (CLYM:NASDAQ)?
The most recent sentiment for CLIMB BIO INC (CLYM:NASDAQ) is .
SEC-8K** Filing Available For CLIMB BIO INC (CLYM:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.